LONDON (Reuters Health) Mar 21 – The European Medicines Evaluation Agency (EMEA) confirmed on Thursday that its scientific committee had initiated a Community-level review on the risk-benefit of Abbott's anti-obesity drug sibutramine (Reductil/Meridia), which was withdrawn from the market in Italy earlier this month after reports that two patients had died.
A spokesman declined to say who was leading the review, which was requested by Italy. Abbott has said that it is aware of 34 deaths globally but insists there is no evidence that these were caused by the drug, which has been used by millions of patients since it was launched in 1997.
סל התרופות כמו אקמול לחולה סרטן/ מאמר אורח מאת ד”ר אודי פרישמן
אין תגובות06/01/2020
מדי שנה רועשת וגועשת התקשורת סביב סל התרופות, מה ייכנס
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!